Wockhardt receives FDA OK for generic Augmentin suspension
This article was originally published in Scrip
Executive Summary
Morton Grove Pharmaceuticals, the Chicago-based subsidiary of India's Wockhardt, has received US FDAapproval for marketing an oral suspension of a combination containing 250mg/5ml of amoxicillin and 62.5mg/5ml of clavulanate potassium, a generic version of GlaxoSmithKline's anti-infective, Augmentin. Wockhardt said that it was the first company to receive an ANDA approval for this strength of Augmentin.
You may also be interested in...
Chiesi Files India Legal Action Against Cipla Over Respiratory Therapy Patent
Novartis Sheds Vildagliptin Trademark In India Ahead Of Patent Expiry
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla's COO Steps Down
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Need a specific report? 1000+ reports available
Buy Reports